Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
US10646521B2 · kind B2 · utility
1Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 21, 2014 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Mar 18, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.